Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018
WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Radius Health, (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2017 financial results on Thursday, March 1, 2018. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.
Conference Call Information
Date: Thursday, March 1, 2018
Time: 4:30 p.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 3484256
Live webcast: https://edge.media-server.com/m6/p/rw74zpqc
A replay of the conference call/webcast will be available from March 1, 2018 at 7:30 p.m. ET until March 8, 2018 at 7:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 3484256.
The live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com, and a webcast replay will also be available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.
About Radius Health
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com, and follow us on Twitter and LinkedIn.
Investor Relations Contact:
Elhan Webb, CFA